BSP:MRCK34 (USA)
Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
2000 Galloping Hill Road, Kenilworth, NJ, USA, 07033
Compare
Compare
Traded in other countries / regions
MRK.Argentina
•
MRK.Austria
•
MRCK34.Brazil
•
MRK.Chile
•
MRK.France
•
6MK.Germany
•
MRK.Mexico
•
MRK.Peru
•
MRK.Romania
•
MRK.Switzerland
•
0QAH.UK
•
MRK.USA
Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.32 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.73 | |||||
| Debt-to-EBITDA | 1.37 | |||||
| Interest Coverage | 21.8 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 4.12 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.7 | |||||
| 3-Year EBITDA Growth Rate | 10.5 | |||||
| 3-Year EPS without NRI Growth Rate | 28 | |||||
| 3-Year FCF Growth Rate | 7.1 | |||||
| 3-Year Book Growth Rate | 13.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 10.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 7.91 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.99 | |||||
| 9-Day RSI | 40.75 | |||||
| 14-Day RSI | 42.36 | |||||
| 6-1 Month Momentum % | 26.23 | |||||
| 12-1 Month Momentum % | 29.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.39 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 0.44 | |||||
| Days Inventory | 143.02 | |||||
| Days Sales Outstanding | 57.61 | |||||
| Days Payable | 82.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.15 | |||||
| Dividend Payout Ratio | 0.42 | |||||
| 3-Year Dividend Growth Rate | 9.9 | |||||
| Forward Dividend Yield % | 3.18 | |||||
| 5-Year Yield-on-Cost % | 4.65 | |||||
| 3-Year Average Share Buyback Ratio | 0.8 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.4 | |||||
| Operating Margin % | 33.87 | |||||
| Net Margin % | 29 | |||||
| ROE % | 43.31 | |||||
| ROA % | 16.46 | |||||
| ROIC % | 23.97 | |||||
| ROC (Joel Greenblatt) % | 96.2 | |||||
| ROCE % | 24.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.62 | |||||
| Forward PE Ratio | 12.2 | |||||
| PE Ratio without NRI | 13.56 | |||||
| Shiller PE Ratio | 27.22 | |||||
| Price-to-Owner-Earnings | 16.1 | |||||
| PEG Ratio | 1.78 | |||||
| PS Ratio | 3.95 | |||||
| PB Ratio | 5.21 | |||||
| Price-to-Free-Cash-Flow | 15.68 | |||||
| Price-to-Operating-Cash-Flow | 11.94 | |||||
| EV-to-EBIT | 12.72 | |||||
| EV-to-Forward-EBIT | 11.07 | |||||
| EV-to-EBITDA | 10.7 | |||||
| EV-to-Forward-EBITDA | 10.52 | |||||
| EV-to-Revenue | 4.32 | |||||
| EV-to-Forward-Revenue | 4.22 | |||||
| EV-to-FCF | 17.14 | |||||
| Price-to-Projected-FCF | 1.89 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.52 | |||||
| Earnings Yield (Greenblatt) % | 7.86 | |||||
| Forward Rate of Return (Yacktman) % | 12.7 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 298,690.691 | ||
| EPS (TTM) (R$) | 4.269 | ||
| Beta | -0.33 | ||
| Volatility % | 32.7 | ||
| 14-Day RSI | 42.36 | ||
| 14-Day ATR (R$) | 1.612918 | ||
| 20-Day SMA (R$) | 59.1575 | ||
| 12-1 Month Momentum % | 29.01 | ||
| 52-Week Range (R$) | 45.5 - 65 | ||
| Shares Outstanding (Mil) | 20,266.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merck & Co Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||